EVOTEC RECEIVES € 150 M LOAN FROM EUROPEAN INVESTMENT BANK
Evotec SE and the European Investment Bank (EIB) announced on February 10, 2023 that an unsecured EIB loan facility of €150 million has been granted to support the company’s research and development activities, equity investments and the building of the new Just - Evotec Biologics J.POD® biologics manufacturing facility on Evotec’s Campus Curie in Toulouse, France.
This first European J.POD facility will allow for massive scale manufacturing of affordable contemporary biologicals, notable monoclonal antibodies, with the aim to create equitable access to those gold standard medications for patients in Europe and Africa.
The transaction was signed by members of Evotec CEO Dr Werner Lanthaler, Evotec CFO Enno Spillner and EIB Vice-President Ambroise Fayolle at a ceremony held on Evotec’s Campus Curie in Toulouse on February 10, 2023. The financing agreement, as well as a previous loan of €75 million granted by the EIB in 2017, has been developed in cooperation with kENUP Foundation.
The public ceremony was held
on
Friday, February 10, 2023
10:00h -10:45h CET
at
Evotec (France) SAS
Campus Curie
195, route d‘Espagne,
31036 Toulouse CEDEX (France)
Speakers included
Dr Werner Lanthaler, Chief Executive Officer, Evotec SE
Enno Spillner, Chief Financial Officer, Evotec SE
Ambroise Fayolle, Vice-President, European Investment Bank
Alessandro Izzo, Director Equity, Growth Capital and Project Finance, European Investment Bank
The signature event was moderated by kENUP Foundation and streamed live on this site.
A recording of the ceremony is available below.
Evotec's Press Release on the financing can be accessed here,
with the European Investment Bank's Press Release available here.